Selective ghrelin/GHSR-1a receptor agonist
PRODUCT PROFILE
Ipamorelin
Price range: £34.99 through £54.99
Ipamorelin is selective ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to pulsatile pituitary gh release through the ghrelin-receptor pathway.
A ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.
- Evidence stageEarly human evidence
- AvailabilityAvailable · select size for stock
- Batch recordOpen COA
- DispatchConfirmed at checkout
SUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review

Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Established clinical evidence

Tesamorelin
£52.99Batch COA availableIt is the GHRH analogue in this catalogue with an authorised indication and outcome trials for a defined…
Available · 50 in stockAdd to basket -
Early human evidence

CJC-1295 DAC
Price range: £32.99 through £39.995 mgBatch COA availableIts albumin-binding extension creates sustained exposure, unlike CJC-1295 No DAC or sermorelin.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Ipamorelin is selective ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to pulsatile pituitary gh release through the ghrelin-receptor pathway.
Research focus+
Researchers study whether it can trigger a focused pulse of growth hormone with fewer effects on other pituitary hormones than older compounds. Reliable long-term human evidence is limited.
How the mechanism differs+
Activates the growth-hormone secretagogue receptor rather than the GHRH receptor; early studies suggested relative GH selectivity.
Evidence and limitations+
Early human pharmacology exists, but there is no established authorised therapeutic indication and outcome evidence is limited.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can trigger a focused pulse of growth hormone with fewer effects on other pituitary hormones than older compounds. Reliable long-term human evidence is limited.
Activates the growth-hormone secretagogue receptor rather than the GHRH receptor; early studies suggested relative GH selectivity.
A ghrelin-receptor secretagogue—not a GHRH analogue—and generally discussed as more selective than older GHRPs.
Early human pharmacology exists, but there is no established authorised therapeutic indication and outcome evidence is limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.






